45 Current news of Qiagen
rss |
You can refine your search further. Select from the filter options on the left to narrow down your results. |
23-Feb-2021
QIAGEN announced the appointment of Thomas Ebeling, a leading international executive with extensive experience in the healthcare, media and consumer goods industries, as a member of the Supervisory Board with immediate effect. Mr. Ebeling joins QIAGEN as part of a process launched by the ...
QIAGEN acquires remaining 80.1% stake in NeuMoDx Molecular, Inc. for $248 million
18-Sep-2020
QIAGEN N.V. announced the acquisition of the remaining 80.1% of diagnostics instruments company NeuMoDx Molecular, Inc. for $248million in cash. The move rounds out QIAGEN’s portfolio of automated molecular testing solutions based on the proven PCR technology. The transaction was completed after ...
Offer price increased
17-Jul-2020
Thermo Fisher Scientific Inc. and QIAGEN N.V. announced that they have entered into an amendment to their acquisition agreement under which Thermo Fisher has commenced a tender offer to acquire all of the ordinary shares of QIAGEN. The amendment provides for an increase from the original offer ...
19-Mar-2020
QIAGEN announced that it has obtained derogation in Germany by the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) for its newly developed QIAstat-Dx Respiratory SARS-CoV-2 Panel test to be sold as an in vitro diagnostic (“IVD”) for the detection of SARS-CoV-2. At the same time, the ...
18-Mar-2020
QIAGEN announced plans to dramatically ramp up global production capacity of RNA extraction kits that are used as part of workflows around the world to detect nucleic acid from SARS-CoV-2, the novel coronavirus that causes COVID-19. QIAGEN has historically allocated global production capacity to ...
03-Mar-2020
Thermo Fisher Scientific Inc. and QIAGEN N.V. announced that their boards of directors, as well as the managing board of QIAGEN N.V., have unanimously approved Thermo Fisher’s proposal to acquire QIAGEN for €39 per share in cash. The offer price represents a premium of approximately 23% to the ...
Peer M. Schatz to step down as CEO
08-Oct-2019
QIAGEN N.V. announced thatPeer M. Schatz, Chief Executive Officer, has notified the Company that, after 27 years at QIAGEN, he has decided to step down as Chief Executive Officer and Chairman of the Management Board. He will remain with QIAGEN as Special Advisor to the Supervisory Board and ...
QIAGEN enters into agreement to acquire STAT-Dx
09-Feb-2018
QIAGEN N.V. announced it has entered into an agreement to acquire STAT-Dx, a privately-held company developing the next generation of multiplex diagnostics for one-step, fully integrated molecular analysis of common syndromes using a novel system based on real-time PCR technology and proven ...
Public-private partnership aims to standardize and clinically validate blood-based biomarkers
31-Mar-2017
QIAGEN N.V. announced it has joined CANCER-ID, a public-private consortium aiming to establish standard protocols and clinical validation for blood-based biomarkers in lung and breast cancer. Rapid advances in the use of liquid biopsies, which enable cancer treatment and monitoring through the ...
06-May-2015
QIAGEN N.V. announced that it has expanded its relationship with BG to provide QIAGEN’s Ingenuity® Variant Analysis™ in integrated bioinformatics for all customers of BGI’s sequencing services.Under the reseller agreement, BGI customers will receive sequencing data generated from their samples ...
